Anthropic CEO Dario Amodei tempered earlier predictions that artificial intelligence would compress a decade of biotech progress into a single year, saying such gains are likely a decade away. Speaking at an event in San Francisco unveiling Claude Science, a product aimed at biologists and pharmaceutical firms, Amodei cited three near-term constraints: current model capability, the time scientists need to integrate new tools, and slow-moving infrastructure and regulatory change. The remarks suggest AI’s biggest promises in drug discovery remain long-term, even as immediate productivity boosts in research workflows may be achievable. Anthropic, a public‑benefit corporation, is positioning its technology for practical lab use while acknowledging the sector’s structural hurdles.
Inside Anthropic’s view on AI’s real timeline for biotech—and what could change now
- Trending
- Comments
- Latest
